open access

Vol 52, No 4 (2018)
Original research articles
Submitted: 2017-12-10
Get Citation

The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease

Anna Pierzchlińska, Monika Białecka, Mateusz Kurzawski, Jarosław Sławek
DOI: 10.1016/j.pjnns.2018.04.003
·
Neurol Neurochir Pol 2018;52(4):477-482.

open access

Vol 52, No 4 (2018)
Original research articles
Submitted: 2017-12-10

Abstract

Apolipoprotein E (ApoE) is a vital component of several lipoproteins and plays a major role in lipid metabolism. APOE gene comprises of three alleles determined by two single nucleotide polymorphisms (rs429358 and rs7412) resulting in the protein isoforms, among which ApoE4 is a confirmed risk factor for Alzheimer's Disease. However, the impact of APOE genotypes on Parkinson's Disease Dementia (PDD) is still inconclusive. The PDD diagnostic criteria are very inconsistent, and could be complemented with genetic factors. Our study covers a total of 237 patients diagnosed with Parkinson's Disease (PD) according to UK PD Brain Bank criteria, who were classified as subjects with (PDD, n equals 73) and without (nPDD, n equals 164) dementia, using neuropsychological assessment tests. TaqMan real-time PCR assays were used to determine APOE allele. No statistically significant differences in APOE alleles frequencies between nPDD and PDD patients have been observed. The study results revealed that the APOE polymorphism is not associated with cognitive status in PD patients.

Abstract

Apolipoprotein E (ApoE) is a vital component of several lipoproteins and plays a major role in lipid metabolism. APOE gene comprises of three alleles determined by two single nucleotide polymorphisms (rs429358 and rs7412) resulting in the protein isoforms, among which ApoE4 is a confirmed risk factor for Alzheimer's Disease. However, the impact of APOE genotypes on Parkinson's Disease Dementia (PDD) is still inconclusive. The PDD diagnostic criteria are very inconsistent, and could be complemented with genetic factors. Our study covers a total of 237 patients diagnosed with Parkinson's Disease (PD) according to UK PD Brain Bank criteria, who were classified as subjects with (PDD, n equals 73) and without (nPDD, n equals 164) dementia, using neuropsychological assessment tests. TaqMan real-time PCR assays were used to determine APOE allele. No statistically significant differences in APOE alleles frequencies between nPDD and PDD patients have been observed. The study results revealed that the APOE polymorphism is not associated with cognitive status in PD patients.

Get Citation

Keywords

Dementia, Genetic polymorphism, Parkinson' s disease, Apolipoprotein E

About this article
Title

The impact of Apolipoprotein E alleles on cognitive performance in patients with Parkinson's disease

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 4 (2018)

Pages

477-482

DOI

10.1016/j.pjnns.2018.04.003

Bibliographic record

Neurol Neurochir Pol 2018;52(4):477-482.

Keywords

Dementia
Genetic polymorphism
Parkinson's disease
Apolipoprotein E

Authors

Anna Pierzchlińska
Monika Białecka
Mateusz Kurzawski
Jarosław Sławek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl